Correction: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

Oncogene. 2023 Dec;42(50):3719. doi: 10.1038/s41388-023-02870-9.

L Venturutti¹, R I Cordo Russo¹, M A Rivas², M F Mercogliano¹, F Izzo¹, R H Oakley³, M G Pereyra^{1

4}, M De Martino¹, C J Proietti¹, P Yankilevich⁵, J C Roa^{6

7

8}, P Guzmán⁶, E Cortese⁹, D H Allemand¹⁰, T H Huang¹¹, E H Charreau¹, J A Cidlowski³, R Schillaci¹, P V Elizalde¹²

¹ Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina.
² Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
³ Department of Health and Human Services, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
⁴ Servicio de Anatomía Patológica, Hospital General de Agudos 'Juan A Fernández', Buenos Aires, Argentina.
⁵ Instituto de Investigación en Biomedicina de Buenos Aires, CONICET-Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
⁶ Departamento de Anatomía Patológica (BIOREN), Universidad de La Frontera, Temuco, Chile.
⁷ Departamento de Anatomía Patológica, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile.
⁸ Advanced Center for Chronic Diseases (ACCDIS), Pontificia Universidad Católica de Chile, Santiago de Chile, Santiago, Chile.
⁹ Servicio de Ginecología, Hospital Aeronáutico Central, Buenos Aires, Argentina.
¹⁰ Unidad de Patología Mamaria, Hospital General de Agudos 'Juan A Fernández', Buenos Aires, Argentina.
¹¹ Department of Molecular Medicine/Institute of Biotechnology, Cancer Therapy and Research Center, University of Texas, San Antonio, TX, USA.
¹² Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina. patriciaelizalde@ibyme.conicet.gov.ar.

No abstract available

Publication types